Key Segmentation
By Product Type
-
Flower
-
Oil & Tinctures
-
Edibles
-
Beverages
-
Other Products
By Application
-
Medical
-
Adult-Use
By Compound
-
THC-Dominant
-
CBD-Dominant
-
Balanced
By Source
-
Marijuana
-
Hemp
By Distribution Channel
-
Dispensaries
-
Online Channels
-
Other Channels
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Curaleaf, Green Thumb Industries, Trulieve, Verano Holdings, Cresco Labs, Ascend Wellness Holdings, Jushi Holdings, TerrAscend, Glass House Brands, Planet 13 Holdings, Canopy Growth, Tilray Brands, Aurora Cannabis, SNDL, Cronos Group and Organigram Global.
Key opportunities include federal rescheduling in the United States, new medical programs in Europe and Asia Pacific, export supply to regulated markets and growth of beverages and low dose products.
Expanding legalization is the main growth factor, supported by medical adoption, product innovation and rising social acceptance of regulated cannabis.
By Product Type, the Flower segment dominated the market in 2025 with an estimated 48.25% share, supported by its familiarity, potency and role as the base for pre-rolls and concentrates.
North America dominated the market with a share of 70.40% in 2025, driven by state-licensed medical and adult-use programs in the United States and a mature adult-use market in Canada.